CJC-1295 Mechanism of Action (Preclinical)
CJC-1295 is a synthetic growth-hormone-releasing hormone (GHRH) analog engineered to extend circulating half-life and enhance somatotroph activation in laboratory models. By binding selectively to the growth-hormone-releasing hormone receptor (GHRHR), this research compound stimulates adenylate cyclase pathways, sustaining growth hormone (GH) secretion and downstream insulin-like growth factor 1 (IGF-1) synthesis. This technical dossier detail the receptor kinetics, intracellular signal transduction, and structural modifications that define the CJC-1295 mechanism of action in vitro and in vivo.
Quick answer
CJC-1295 is a synthetic growth-hormone-releasing hormone (GHRH) analog engineered to extend circulating half-life and enhance somatotroph activation in laboratory models. By binding selectively to the growth-hormone-releasing hormone receptor (GHRHR), this research compound stimulates adenylate cyclase pathways, sustaining growth hormone (GH) secretion and downstream insulin-like growth factor 1 (IGF-1) synthesis. This technical dossier detail the receptor kinetics, intracellular signal transduction, and structural modifications that define the CJC-1295 mechanism of action in vitro and in vivo.
Key takeaways
- [CJC-1295](/research-peptides/cjc-1295-no-dac) is a 29-amino acid tetrasubstituted peptide derivative of endogenous growth-hormone-releasing hormone (GHRH 1-29).
- The primary molecular target of the [CJC-1295](/research-peptides/cjc-1295-no-dac) mechanism of action is the GHRH receptor (GHRHR), a class B G-protein-coupled receptor (GPCR) expressed predominantly on the plasma membrane of anterior pituitary somatotroph cells.
- Binding of [CJC-1295](/research-peptides/cjc-1295-no-dac) to GHRHR triggers a classic signal transduction cascade mediated by the heterotrimeric G-protein subunit Gαs.
- A key distinction in [CJC-1295](/research-peptides/cjc-1295-no-dac) research involves the presence or absence of the Drug Affinity Complex (DAC).
Introduction to CJC-1295 as a GHRH Analog
CJC-1295 is a 29-amino acid tetrasubstituted peptide derivative of endogenous growth-hormone-releasing hormone (GHRH 1-29). In endogenous endocrine physiology, GHRH is synthesized in the arcuate nucleus of the hypothalamus and travels through the hypophyseal portal system to act upon anterior pituitary somatotrophs. Endogenous GHRH, however, exhibits an extremely brief biological half-life—typically under 10 minutes in animal models—due to rapid enzymatic cleavage by dipeptidyl peptidase IV (DPP-IV) between the second (Ala) and third (Asp) N-terminal residues.
To overcome rapid clearance in research settings, molecular bioengineers modified the native peptide sequence to create CJC-1295. By substituting specific amino acids at positions 2, 8, 15, and 27 (D-Ala, Gln, Ala, and Leu, respectively), the molecule gains significant steric resistance against enzymatic degradation while preserving high affinity for the target GHRH receptor. Researchers investigating growth hormone secretagogues utilize CJC-1295 to evaluate sustained somatotroph signaling without the hyper-pulsatile degradation curves characteristic of native fragments.
Receptor Binding Dynamics and GHRHR Affinities
The primary molecular target of the CJC-1295 mechanism of action is the GHRH receptor (GHRHR), a class B G-protein-coupled receptor (GPCR) expressed predominantly on the plasma membrane of anterior pituitary somatotroph cells. In vitro ligand-binding assays demonstrate that CJC-1295 retains nanomolar affinity for the extracellular ligand-binding domain of GHRHR, mimicking the natural conformation required to initiate receptor activation.
Upon ligand interaction, the extracellular domain undergoes a structural reorientation that stabilizes the active state of the GPCR. Competitive binding assays in murine and porcine pituitary membrane preparations confirm that CJC-1295 exhibits binding kinetics comparable to native GHRH (1-44), but with a drastically reduced rate of receptor dissociation. This sustained receptor occupancy maintains the transducer state required for prolonged downstream cascade propagation, making it a critical tool in cellular endocrinology studies.
Intracellular Signal Transduction Pathways
Binding of CJC-1295 to GHRHR triggers a classic signal transduction cascade mediated by the heterotrimeric G-protein subunit Gαs. Activation of Gαs leads to the immediate stimulation of membrane-bound adenylate cyclase (AC), which catalyzes the conversion of intracellular adenosine triphosphate (ATP) into cyclic adenosine monophosphate (cAMP).
Elevated intracellular cAMP levels directly activate Protein Kinase A (PKA). Active PKA phosphorylates several downstream target proteins, including the cyclic AMP response element-binding protein (CREB). Translocation of phosphorylated CREB to the nucleus induces transcription of the growth hormone gene (*GH1*). Concurrently, PKA activation mediates the influx of extracellular calcium ions ($Ca^{2+}$) through L-type voltage-gated calcium channels, prompting the exocytosis of pre-stored GH secretory vesicles into the pericapillary space. In vitro studies using isolated somatotroph cultures show that CJC-1295 sustains cAMP elevation significantly longer than unmodified GHRH analogs.
Bioconjugation and the Role of the Drug Affinity Complex (DAC)
A key distinction in CJC-1295 research involves the presence or absence of the Drug Affinity Complex (DAC). The inclusion of a maleimido-propionic acid linker at the C-terminus enables CJC-1295 with DAC to form a covalent bioconjugate with endogenous serum albumin following administration in animal models. Serum albumin possesses a reactive thiol group at Cys-34, which selectively attacks the maleimide group on the DAC moiety via a Michael addition reaction.
This covalent binding to albumin shields the peptide backbone from renal filtration and enzymatic proteolysis by DPP-IV and neutral endopeptidases (NEP). While un-complexed CJC-1295 (often designated as modified GRF 1-29) exhibits a half-life of approximately 30 minutes in rodent models, the albumin-bound DAC variant displays an extended half-life exceeding 6 to 8 days. Researchers select between these variants based on whether the experimental model requires baseline continuous elevation or acute, discrete somatotroph stimulation.
Downstream Hepatic IGF-1 Synthesis and Endocrine Cascades
The biological consequences of GHRHR stimulation extend far beyond the pituitary gland. Once released into circulation, growth hormone travels to peripheral tissues, primarily target cells within the liver. GH binds to transmembrane growth hormone receptors (GHR), which dimerize and activate the Janus kinase 2 (JAK2) / Signal Transducer and Activator of Transcription 5 (STAT5) signaling cascade.
In laboratory models, STAT5 phosphorylation leads to upregulated transcription and secretion of Insulin-Like Growth Factor 1 (IGF-1) and its primary binding protein, IGFBP-3. IGF-1 acts as the primary systemic mediator of growth hormone activity, driving anabolic processes in chondrocytes, osteoblasts, and myoblasts. In vivo rodent assays demonstrate that continuous elevation of serum GH induced by CJC-1295 results in proportional, sustained increases in circulating IGF-1 concentrations, providing a stable baseline for researching growth factor signaling pathways.
Comparative Analysis: CJC-1295 vs. Alternative Secretagogues
Within preclinical growth factor research, CJC-1295 is frequently evaluated alongside other synthetic GHRH analogs and growth hormone secretagogue receptor (GHSR) agonists. Understanding the mechanical differences between these classes is vital for structuring comparative in vitro and animal models.
While CJC-1295 acts as a direct GHRH receptor agonist, compounds such as Sermorelin represent shorter, non-tetrasubstituted sequences that undergo faster enzymatic degradation. Conversely, Tesamorelin features a trans-3-hexenoic acid modification tailored for distinct lipolytic research models. Furthermore, ghrelin receptor agonists like Ipamorelin operate through an entirely distinct signaling network (GHSR-1a via the $IP_3$/DAG pathway) rather than the cAMP/PKA pathway. Combining a GHRH analog like CJC-1295 with a GHSR agonist is frequently studied in preclinical research to observe synergistic somatotroph activation.
Preclinical Applications in Tissue Repair and Metabolic Research
Due to its capacity to sustain elevated GH and IGF-1 levels, CJC-1295 serves as an important research tool across various biomedical disciplines. In rodent models of musculoskeletal injury, sustained IGF-1 expression downstream of CJC-1295 administration has been correlated with accelerated satellite cell proliferation and collagen synthesis in damaged tendon and skeletal muscle tissue.
In metabolic research, preclinical assays evaluate how extended GHRHR activation impacts lipid mobilization and nitrogen retention. Growth hormone induces lipolysis by upregulating hormone-sensitive lipase (HSL) in adipocytes, while IGF-1 promotes amino acid uptake and protein synthesis in lean tissue. Investigating these metabolic parameters helps researchers map the cellular cascades governing nutrient partitioning and cellular regeneration under stressed or ischemic conditions.
Analytical Characterization and Quality Verification at PX1 Research
To ensure precise and reproducible experimental outcomes, laboratory research reagents must adhere to rigorous analytical standards. Reagents sourced for in vitro assays or preclinical animal models must be verified for identity, purity, and freedom from biological contaminants that could alter baseline cell signaling.
At PX1 Research, every lot of CJC-1295 is synthesized in state-of-the-art USA-based facilities operating under GMP compliance. Quality control protocols utilize high-performance liquid chromatography (HPLC) paired with mass spectrometry (MS) performed in an ISO 17025 accredited laboratory to guarantee greater than 99% peptide purity. Additionally, rigorous kinetic chromogenic assays confirm that bacterial endotoxin levels remain well below strict threshold limits (<0.01 EU/mg), ensuring that somatotroph signaling assays remain free from inflammatory artifacts caused by lipopolysaccharides.
Handling, Storage, and Reconstitution for Laboratory Protocols
Maintaining peptide integrity is essential for generating reliable quantitative data. Lyophilized CJC-1295 should be stored in a sub-zero environment, ideally at -20°C or -80°C, protected from light and moisture to prevent hydrolysis or oxidation of key residue side chains.
When preparing solutions for laboratory experimentation, reconstitution should be performed using sterile, bacteriostatic water or laboratory-grade phosphate-buffered saline (PBS). Avoid vigorous vortexing, as mechanical shear stress can denature tertiary structural elements; gentle swirling or passive dissolution is recommended. For precise volumetric calculations during experimental design, researchers can utilize our peptide reconstitution calculator to ensure accurate final molar concentrations. For high-throughput institutional studies, custom bulk quantities are accessible via our wholesale lab account portal.
Frequently Asked Questions
What is the specific receptor target for CJC-1295?
CJC-1295 targets the Growth-Hormone-Releasing Hormone Receptor (GHRHR), a class B G-protein-coupled receptor located on anterior pituitary somatotrophs.
How does the CJC-1295 mechanism of action differ between DAC and No DAC variants?
CJC-1295 with DAC contains a maleimide linker that covalently binds to circulating serum albumin in animal models, extending the half-life to several days. CJC-1295 without DAC (modified GRF 1-29) lacks this linker, resulting in a half-life of approximately 30 minutes for short-duration acute signaling assays.
What intracellular pathway is stimulated by CJC-1295 binding?
Binding to GHRHR activates the Gαs protein subunit, stimulating adenylate cyclase to produce cAMP. Elevated cAMP activates Protein Kinase A (PKA), which phosphorylates CREB to induce growth hormone gene transcription and influx of calcium ions for GH exocytosis.
Why are tetrasubstitutions added to the CJC-1295 peptide chain?
The four amino acid substitutions (D-Ala2, Gln8, Ala15, Leu27) protect the peptide backbone from cleavage by dipeptidyl peptidase IV (DPP-IV) and other endogenous proteases, significantly improving metabolic stability compared to native GHRH (1-29).
How does CJC-1295 influence downstream IGF-1 levels in preclinical models?
By stimulating pituitary growth hormone release, GH subsequently binds to hepatic GH receptors, triggering the JAK2/STAT5 pathway to synthesize and secrete insulin-like growth factor 1 (IGF-1) into circulation.
What analytical methods verify the purity of CJC-1295 from PX1 Research?
PX1 Research verifies every lot using High-Performance Liquid Chromatography (HPLC) to confirm peptide purity (>99%) and Mass Spectrometry (MS) to confirm exact molecular weight, conducted in ISO 17025 accredited laboratories.
How should reconstituted CJC-1295 be stored in a laboratory environment?
Reconstituted CJC-1295 solutions should be stored at 2°C to 8°C and used within short experimental windows to prevent degradation, or aliquot-frozen at -20°C to avoid repeated freeze-thaw cycles.
Can CJC-1295 be studied alongside GHRP compounds like Ipamorelin in vitro?
Yes. Preclinical studies frequently combine GHRH analogs like CJC-1295 with GHSR agonists like Ipamorelin to investigate additive or synergistic somatotroph signaling, as they operate through complementary intracellular pathways (cAMP/PKA vs. IP3/DAG).
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.